Médecine

Paramédical

Autres domaines


S'abonner

Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas - 27/12/17

Doi : 10.1016/j.jaad.2017.06.003 
Andre Vadimovich Moyakine, MD , Bjorn Herwegen, BSc, Catharina Joanna Maria van der Vleuten, MD, PhD
 Department of Dermatology, Hecovan Expertise-Center for Hemangioma and Vascular Malformations, Radboud University Medical Center, Nijmegen, The Netherlands 

Reprint requests: Andre Vadimovich Moyakine, MD, Rene Descartesdreef 1, 6525 GL, Nijmegen, The Netherlands.Rene Descartesdreef 1, 6525 GLNijmegenThe Netherlands

Abstract

Background

The Hemangioma Severity Scale (HSS) assesses the severity of an infantile hemangioma (IH).

Objective

First, to compare HSS scores between patients with IH for whom propranolol treatment was indicated at their first visit and those who were not treated. Second, to assess suitable cutoff values for the need for propranolol treatment.

Method

All patients with IH who attended our tertiary referral center since 2008 and were 0 to 6 months of age at their first visit were included. They were divided into propranolol and no-propranolol groups on the basis of choice of treatment at their first visit. HSS scores were assessed, and median scores were compared.

Results

A total of 657 children (342 in the propranolol group) were included. The median HSS score (25th-75th percentile) in the propranolol group was 10 (range, 8-14) compared with 7 (range, 4-9) in the no-propranolol group (P < .001). Cutoff values of 6 or lower (no indication for treatment) and 11 or higher (indication for treatment) resulted in 94% sensitivity and 89% specificity, respectively.

Limitations

HSS scoring was not completely blinded.

Conclusion

The HSS with cutoff values of 6 or lower and 11 or higher could be used as a triage tool for propranolol treatment. Patient age, IH type, and parental preference may also contribute to treatment decisions.

Le texte complet de cet article est disponible en PDF.

Key words : clinical practice, cutoff values, infantile hemangioma, propranolol, severity, treatment indication

Abbreviations used : AUC, HSS, IH


Plan


 Funding sources: None.
 Conflicts of interest: None declared.
 Dr Moyakine participated in generating, gathering, and interpreting the data for the study, and he wrote the majority of the original draft of the paper and approved the final version of this paper. Mr Herwegen participated in generating and gathering the data for the study and writing the paper, and he approved the final version of this paper. Dr van der Vleuten devised the design of the study and participated in generating and gathering the data for the study and writing the paper; she approved the final version of this paper and guarantees that all individuals who meet the authorship criteria of the Journal of the American Academy of Dermatology are included as authors of this paper.


© 2017  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 77 - N° 5

P. 868-873 - novembre 2017 Retour au numéro
Article précédent Article précédent
  • Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves
  • Yukari Zenke, Yuri Ohara, Daiki Kobayashi, Satoru Arai, Mitsumasa Kishimoto, Masato Okada, Hikaru Eto
| Article suivant Article suivant
  • Wilms tumor screening in diffuse capillary malformation with overgrowth and macrocephaly–capillary malformation: A retrospective study
  • Caitlin M. Peterman, Sophie Vadeboncoeur, John B. Mulliken, Steven J. Fishman, Marilyn G. Liang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.